Clarithromycin

Generic Name
Clarithromycin
Brand Names
Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500
Drug Type
Small Molecule
Chemical Formula
C38H69NO13
CAS Number
81103-11-9
Unique Ingredient Identifier
H1250JIK0A
Background

Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Indication

An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).

Clarithromycin is indicated in combination with vonoprazan and amoxicillin as co-packaged triple therapy to treat Helicobacter pylori (H. pylori) infection in adults.

Associated Conditions
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections
Associated Therapies
-

Clarithromycin in Multiple Myeloma Induction Therapy

First Posted Date
2015-10-12
Last Posted Date
2016-09-20
Lead Sponsor
Henrik Gregersen
Target Recruit Count
58
Registration Number
NCT02573935
Locations
🇩🇰

Department of Hematology, Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Department of Hematology, Herlev Hospital, Herlev, Denmark

and more 4 locations

Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma

First Posted Date
2015-09-07
Last Posted Date
2023-09-01
Lead Sponsor
Joseph Tuscano
Target Recruit Count
30
Registration Number
NCT02542657
Locations
🇺🇸

University of California Irvine, Orange, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

First Posted Date
2015-08-06
Last Posted Date
2023-06-05
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
12
Registration Number
NCT02516696
Locations
🇺🇸

University of Colorado - Anschutz Cancer Center, Aurora, Colorado, United States

🇺🇸

Weill Cornell Medical College, New York, New York, United States

Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients

First Posted Date
2015-06-09
Last Posted Date
2016-09-02
Lead Sponsor
Chung-Tai Wu
Target Recruit Count
114
Registration Number
NCT02466919

Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori

First Posted Date
2015-04-21
Last Posted Date
2017-04-25
Lead Sponsor
Sherief Abd-Elsalam
Target Recruit Count
120
Registration Number
NCT02422706
Locations
🇪🇬

Tanta university hospital, Cairo, Egypt

Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2015-04-15
Last Posted Date
2016-09-16
Lead Sponsor
University of Nottingham
Target Recruit Count
1
Registration Number
NCT02416570

Dabigatran in an Interaction Probe Drug Cocktail

First Posted Date
2015-02-12
Last Posted Date
2018-08-14
Lead Sponsor
Turku University Hospital
Target Recruit Count
16
Registration Number
NCT02361619
Locations
🇫🇮

Teutori CPRU, Turku, Finland

Selinexor and Backbone Treatments of Multiple Myeloma Patients

First Posted Date
2015-01-21
Last Posted Date
2024-05-07
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
300
Registration Number
NCT02343042
Locations
🇺🇸

Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

and more 21 locations

Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy

First Posted Date
2014-11-20
Last Posted Date
2015-09-03
Lead Sponsor
Xijing Hospital of Digestive Diseases
Target Recruit Count
612
Registration Number
NCT02296021
Locations
🇨🇳

Xijing Hospital of Digestive Diseases, Xi'an, Shanxi, China

© Copyright 2024. All Rights Reserved by MedPath